Global Epilepsy Diagnosis & Treatment 麻豆原创 Research Report 2024

Publication ID:

PB501242234

Publication Date:

January 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Epilepsy is a neurological disorder affecting the central nervous system. In this medical condition, the brain exhibits abnormal activity, which results in periods of unusual behavior or seizures and sometimes, loss of awareness. Temporary confusion, anxiety, uncontrollable jerking movements of the arms and legs, and others are some of the common symptoms of the disease.
The global Epilepsy Diagnosis & Treatment market was valued at US$ 3065.2 million in 2023 and is anticipated to reach US$ 5357.7 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
Increasing prevalence of epilepsy is a major driver for the market. According to a report by the World Health Organization (2018), about 50 million people across the world are estimated to suffer from epilepsy, making it one of the most common neurological diseases. In addition, the report states that the total number of people aged 65 or more is projected to increase from 524 million in 2010 to approximately 1.5 billion by 2050.
This report aims to provide a comprehensive presentation of the global market for Epilepsy Diagnosis & Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epilepsy Diagnosis & Treatment.
Report Scope
The Epilepsy Diagnosis & Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epilepsy Diagnosis & Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epilepsy Diagnosis & Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Johnson & Johnson
UCB Pharma
Abbott
GlaxoSmithKline
Novartis
Sanofi
Takeda
Medtronic
Natus Medical
Siemens
Segment by Type
Diagnosis (Neurological Exam, Blood Test, Imaging)
Treatment (Medication, Surgery)
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Epilepsy Diagnosis & Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Epilepsy Diagnosis & Treatment 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diagnosis (Neurological Exam, Blood Test, Imaging)
1.2.3 Treatment (Medication, Surgery)
1.3 麻豆原创 by Application
1.3.1 Global Epilepsy Diagnosis & Treatment 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Epilepsy Diagnosis & Treatment 麻豆原创 Perspective (2019-2030)
2.2 Epilepsy Diagnosis & Treatment Growth Trends by Region
2.2.1 Global Epilepsy Diagnosis & Treatment 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Epilepsy Diagnosis & Treatment Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Epilepsy Diagnosis & Treatment Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Epilepsy Diagnosis & Treatment 麻豆原创 Dynamics
2.3.1 Epilepsy Diagnosis & Treatment Industry Trends
2.3.2 Epilepsy Diagnosis & Treatment 麻豆原创 Drivers
2.3.3 Epilepsy Diagnosis & Treatment 麻豆原创 Challenges
2.3.4 Epilepsy Diagnosis & Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Epilepsy Diagnosis & Treatment Players by Revenue
3.1.1 Global Top Epilepsy Diagnosis & Treatment Players by Revenue (2019-2024)
3.1.2 Global Epilepsy Diagnosis & Treatment Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Epilepsy Diagnosis & Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Epilepsy Diagnosis & Treatment Revenue
3.4 Global Epilepsy Diagnosis & Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Epilepsy Diagnosis & Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Epilepsy Diagnosis & Treatment Revenue in 2023
3.5 Epilepsy Diagnosis & Treatment Key Players Head office and Area Served
3.6 Key Players Epilepsy Diagnosis & Treatment Product Solution and Service
3.7 Date of Enter into Epilepsy Diagnosis & Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Epilepsy Diagnosis & Treatment Breakdown Data by Type
4.1 Global Epilepsy Diagnosis & Treatment Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Epilepsy Diagnosis & Treatment Forecasted 麻豆原创 Size by Type (2025-2030)
5 Epilepsy Diagnosis & Treatment Breakdown Data by Application
5.1 Global Epilepsy Diagnosis & Treatment Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Epilepsy Diagnosis & Treatment Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Epilepsy Diagnosis & Treatment 麻豆原创 Size (2019-2030)
6.2 North America Epilepsy Diagnosis & Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2019-2024)
6.4 North America Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Epilepsy Diagnosis & Treatment 麻豆原创 Size (2019-2030)
7.2 Europe Epilepsy Diagnosis & Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2019-2024)
7.4 Europe Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Epilepsy Diagnosis & Treatment 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Epilepsy Diagnosis & Treatment 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Epilepsy Diagnosis & Treatment 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Epilepsy Diagnosis & Treatment 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Epilepsy Diagnosis & Treatment 麻豆原创 Size (2019-2030)
9.2 Latin America Epilepsy Diagnosis & Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Epilepsy Diagnosis & Treatment 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Epilepsy Diagnosis & Treatment 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Epilepsy Diagnosis & Treatment 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Epilepsy Diagnosis & Treatment Introduction
11.1.4 Pfizer Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Epilepsy Diagnosis & Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 UCB Pharma
11.3.1 UCB Pharma Company Detail
11.3.2 UCB Pharma Business Overview
11.3.3 UCB Pharma Epilepsy Diagnosis & Treatment Introduction
11.3.4 UCB Pharma Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.3.5 UCB Pharma Recent Development
11.4 Abbott
11.4.1 Abbott Company Detail
11.4.2 Abbott Business Overview
11.4.3 Abbott Epilepsy Diagnosis & Treatment Introduction
11.4.4 Abbott Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.4.5 Abbott Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Epilepsy Diagnosis & Treatment Introduction
11.5.4 GlaxoSmithKline Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Epilepsy Diagnosis & Treatment Introduction
11.6.4 Novartis Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Epilepsy Diagnosis & Treatment Introduction
11.7.4 Sanofi Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Epilepsy Diagnosis & Treatment Introduction
11.8.4 Takeda Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Medtronic
11.9.1 Medtronic Company Detail
11.9.2 Medtronic Business Overview
11.9.3 Medtronic Epilepsy Diagnosis & Treatment Introduction
11.9.4 Medtronic Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.9.5 Medtronic Recent Development
11.10 Natus Medical
11.10.1 Natus Medical Company Detail
11.10.2 Natus Medical Business Overview
11.10.3 Natus Medical Epilepsy Diagnosis & Treatment Introduction
11.10.4 Natus Medical Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.10.5 Natus Medical Recent Development
11.11 Siemens
11.11.1 Siemens Company Detail
11.11.2 Siemens Business Overview
11.11.3 Siemens Epilepsy Diagnosis & Treatment Introduction
11.11.4 Siemens Revenue in Epilepsy Diagnosis & Treatment Business (2019-2024)
11.11.5 Siemens Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Johnson & Johnson
UCB Pharma
Abbott
GlaxoSmithKline
Novartis
Sanofi
Takeda
Medtronic
Natus Medical
Siemens

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.